Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Growth Hormone Treatment in Turner Syndrome Extension
NCT00266656Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2005
- Primary completion
- Sep 2015
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, open-label trial of somatropin in Turner syndrome (TS) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Most Mature Height Standard Deviation Score at 10 years. Started Dec 2005; status: completed.
02
Drugs
somatropin
03
Conditions
Turner syndrome (TS)
Beyond the preview
Go deeper on NCT00266656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266656.